Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors

16 Nov 2022

Abstract excerpt

BACKGROUND: Cytopenia is one of the most common adverse events following the CAR-T cell infusion, affecting the quality of life and potentially leading to life-threatening bleeding and infection. This study aimed to systematically review the cytopenias following anti-CD19 CAR-T therapy and further analyse the contributing factors. METHODS: Databases including PubMed, MEDLINE, Embase and Cochrane were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosimilars and Bioanalytical Methods
Share to CAR-T cell therapy research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36382675
DOI: 10.1080/07853890.2022.2136748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factorsPMID 36382675Read ↗

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current managementSemantic proximity Read ↗

Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapySemantic proximity Read ↗

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapySemantic proximity Read ↗

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasSemantic proximity Read ↗

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read ↗

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read ↗

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.Semantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapySemantic proximity Read ↗

A meta-analysis on safety and efficacy of CD19 directed CAR T-cells generated using sleeping beauty transposon systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.